Category: ACN Newswire

Hengdeli Announces 2025 Interim Results

HONG KONG, Aug 20, 2025 – (ACN Newswire via SeaPRwire.com) – Hengdeli Holdings Limited (“Hengdeli” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 3389) announced its interim results for the six months ended 30 June 2025 (“the

More

Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins

BRISBANE, AUS, Aug 19, 2025 – (ACN Newswire via SeaPRwire.com) – Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease

More

The 35th Food Expo opens today

HONG KONG, Aug 14, 2025 – (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the five-day (14-18 August) Food Expo, Beauty & Wellness Expo and Home Delights Expo open to the public from today at the Hong Kong

More

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

HONG KONG, Aug 15, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the “Updated Guidelines”). Etrasimod, an S1P receptor modulator, is recommended

More